Sponsor link https://www.ctf.org/funding-opportunities?utm_source=email&utm_medium=ma...

The purpose of the CRA is to advance effective clinical therapies for neurofibromatosis by supporting early-stage investigations of broad-thinking, novel ideas involving candidate therapeutics, neurocognitive or psychosocial interventions, and clinical-trial-enabling studies.

Examples of areas of interest for this award include, but are not limited to, the following:

• Pilot clinical trials or studies adjunct to an ongoing clinical trial
• Biomarker studies (e.g. molecular, imaging, or genetic biomarkers) that may inform or accelerate a clinical trial or the development of diagnostics
• Patient-reported outcome measures or other real-world evidence that can assess disease burden, risk stratification, short- or long-term treatment effects etc. for specific manifestations
• Natural history
• Clinical heterogeneity and its relation to genetic, environmental, or biologic factors
• Adult care concerns such as barriers to care, transition from pediatric to adult healthcare, chronic pain management, mental health, nutrition, bone/joint health, and sexual and reproductive health
• Research in support of developing evidence-based care and treatment guidelines